Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Sep;38(5):446-449.
doi: 10.3343/alm.2018.38.5.446.

Asymmetrical Dimethylarginine Levels in Hepatitis B Virus-Positive Patients

Faruk Karakecili  1 , Aytekin Cikman  2   3 , Merve Aydin  2   3 , Baris Gulhan  2
Affiliations

Asymmetrical Dimethylarginine Levels in Hepatitis B Virus-Positive Patients

Faruk Karakecili et al. Ann Lab Med. 2018 Sep.

Abstract

Background: High asymmetrical dimethylarginine (ADMA) levels have been associated with endothelial dysfunction and contribute to the development of several diseases. However, data on the relationship between hepatitis B virus (HBV) and ADMA are limited. The aim of our study was to explore the relationship between ADMA and HBV by comparing the ADMA levels in patients with chronic active hepatitis B (CHB), inactive HBV carriers (carriers), and healthy volunteers (controls).

Methods: The participants were divided into three groups: 90 patients with CHB, 90 HBV carriers, and 90 controls. Serum ADMA levels were quantified using an ELISA kit (Cusabio, Wuhan, China). The data were analyzed using an ANOVA or the Kruskal-Wallis test as appropriate, with P<0.05 considered significant.

Results: Serum ADMA levels were significantly higher in patients with CHB (228.35±91.10 ng/mL) than in HBV carriers (207.80±75.80 ng/mL) and controls (207.61±89.10 ng/mL) (P=0.049). The clinical scores of the patients were positively correlated with ADMA levels.

Conclusions: The elevated serum ADMA levels in patients with CHB confirm that HBV plays a role in vasculitis. Further investigation of the mechanisms contributing to the high levels of ADMA in CHB may contribute toward development of new treatment modalities.

Keywords: Asymmetric dimethylarginine; Chronic active hepatitis B; Hepatitis B virus; Inactive hepatitis B virus carrier.

PubMed Disclaimer

Conflict of interest statement

No potential conflicts of interest relevant to this article were reported.

Similar articles

See all similar articles

Cited by

References

    1. Aldámiz-Echevarría L, Andrade F. Asymmetric dimethylarginine, endothelial dysfunction and renal disease. Int J Mol Sci. 2012;13:11288–11311. - PMC - PubMed
    1. Liu X, Hou L, Xu D, Chen A, Yang L, Zhuang Y, et al. Effect of asymmetric dimethlarginine (ADMA) on heart failure development. Nitric Oxide. 2016;54:73–81. - PMC - PubMed
    1. Tain YL, Hsu CN. Toxic dimethylarginines: asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) Toxins (Basel) 2017;9:E92. doi: 10.3390/toxins9030092. - DOI - PMC - PubMed
    1. McCarty MF. Asymmetric dimethylarginine is a well-established mediating risk factor for cardiovascular morbidity and mortality-should patients with elevated levels be supplemented with citrulline? Healthcare (Basel) 2016;4:E40. doi: 10.3390/healthcare4030040. - DOI - PMC - PubMed
    1. Erbil MK, Kurt YG, Yaman H, Çaır E, Akgül EÖ, Çaycı T. Metabolism of asymmetric dimethylarginine and its clinical significance. Turk J Bioch. 2012;37:99–105.

LinkOut - more resources